Results 81 to 90 of about 11,649,511 (362)

The Influence of Safety, Efficacy, and Medical Condition Severity on Natural v. Synthetic Drug Preference

, 2016
Research indicates that there is a preference for natural v. synthetic products, but the influence of this preference on drug choice in the medical domain is largely unknown.
Lappas, Courtney M., Meier, Brian P.
core   +1 more source

A novel multifunctional biomedical material based on polyacrylonitrile:preparation and characterization [PDF]

, 2016
Wet spun microfibers have great potential in the design of multifunctional controlled release materials. Curcumin (Cur) and vitamin E acetate (Vit. E Ac) were used as a model drug system to evaluate the potential application of the drug-loaded microfiber
Bremner, David H., Li, He-yu, Shi, Qi-quan, Wu, Huan-ling, Wu, Jun-zi, Xiao, Rui-qiu, Zhu, Li-min   +6 more
core   +3 more sources

Molecular Docking: Shifting Paradigms in Drug Discovery

International Journal of Molecular Sciences, 2019
Molecular docking is an established in silico structure-based method widely used in drug discovery. Docking enables the identification of novel compounds of therapeutic interest, predicting ligand-target interactions at a molecular level, or delineating ...
Luca Pinzi, G. Rastelli
semanticscholar   +1 more source

Multi‐omic characterization of consensus molecular subtype 1 (CMS1) colorectal cancer with dampened immune response improves precision medicine

Molecular Oncology, EarlyView.
This study highlights the importance of multi‐omic analyses in characterizing colorectal cancers. Indeed, our analysis revealed a rare CMS1 exhibiting dampened immune activation, including reduced PD‐1 expression, moderate CD8+ T‐cell infiltration, and suppressed JAK/STAT pathway.
Livia Concetti, Manuel Scimeca, Julia Bischof, Jonathan Woodsmith, Massimiliano Agostini, Cristina Fiorani, Yufang Shi, Eleonora Candi, Gerry Melino, Alessandro Mauriello, Giuseppe S. Sica   +10 more
wiley   +1 more source

Breaking the paradigm: Dr Insight empowers signature-free, enhanced drug repurposing [PDF]

, 2019
Motivation: Transcriptome-based computational drug repurposing has attracted considerable interest by bringing about faster and more cost-effective drug discovery.
Baldwin, Nicole E., Chan, Jinyan, Gu, Jinghua, Turner, Jacob A., Wang, Xuan   +4 more
core   +1 more source

Systematic review of the safety of medication use in inpatient, outpatient and primary care settings in the Gulf Cooperation Council countries [PDF]

, 2018
Background Errors in medication use are a patient safety concern globally, with different regions reporting differing error rates, causes of errors and proposed solutions.
Abu Yassin, Abushaiqa, Ackroyd-Stolarz, Al Anany, Al Anazi, Al Hamid, Al Khaja, Al Khaja, Al Khaja, Al Khaja, Al Khaja, Al Odhayani, Al Rahbi, Al Shahaibi, Al-Arifi, Al-Arifi, Al-Dhawailie, Al-Ghamdi, Al-Hussein, Al-Jazairi, Al-Jeraisy, Al-Khani, Al-Olah, Al-Omar, Al-Rashdi, Al-Rowibah, Al-Tajir, Alakhali, Alanazi, Albarrak, Alghamdy, Aljadhey, Aljadhey, Aljadhey, Aljamal, Allan, Almazrou, Alshaikh, Alsulaimi, Altebenaui, American Geriatrics Society Beers Criteria Update Expert Panel, Arabi, Aseeri, ASHP, Bates, Bryony Dean Franklin, Cohen, Dean, Dean, Dean, Dean, Dibbi, Elnour, Ferner, Fick, Flynn, Flynn, Gandhi, Ghaleb, Ghaleb, Hemida, Hepler, Hisham Saad Aljadhey, Hooper, Insley, Irshaid, Jamilah Alsaidan, Jane Portlock, Jha, Jha, Kaushal, Kheir, Khoja, Landis, Lisby, Mahmoud, McLeod, McPhillips, Mendonca, Miller, Mitwally, Morimoto, Morimoto, Nada Atef Shebl, Naranjo, Nebeker, Neville, Rancourt, Rashed, Rashed, Rehmani, Sadat-Ali, Shaughnessy, Sonallah, WHO, World Bank   +95 more
core   +3 more sources

Targeting the AKT/mTOR pathway attenuates the metastatic potential of colorectal carcinoma circulating tumor cells in a murine xenotransplantation model

Molecular Oncology, EarlyView.
Dual targeting of AKT and mTOR using MK2206 and RAD001 reduces tumor burden in an intracardiac colon cancer circulating tumor cell xenotransplantation model. Analysis of AKT isoform‐specific knockdowns in CTC‐MCC‐41 reveals differentially regulated proteins and phospho‐proteins by liquid chromatography coupled mass spectrometry. Circulating tumor cells
Daniel J. Smit, Thais Pereira‐Veiga, Helena Brauer, Michael Horn, Paula Nissen, Thomas Mair, Bente Siebels, Hannah Voß, Ruimeng Zhuang, Marie‐Therese Haider, Desiree Loreth, Margarita Iskhakova, Bele Lindemann, Julian Kött, Laure Cayrefourcq, Jasmin Wellbrock, Hartmut Schlüter, Klaus Pantel, Catherine Alix‐Panabières, Manfred Jücker   +19 more
wiley   +1 more source

Choosing the safest acute combination therapy during prophylactic treatment. pharmacokinetic and pharmacodynamic considerations [PDF]

, 2015
Drugs used in the treatment of migraine have been recently reported to be highly associated with the occurrence of clinically significant drug-drug interactions (DDIs)
Lionetto, Luana, MARTELLETTI, Paolo
core   +1 more source

MET and NF2 alterations confer primary and early resistance to first‐line alectinib treatment in ALK‐positive non‐small‐cell lung cancer

Molecular Oncology, EarlyView.
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu, Ning Ding, Xiaobo Xu, Yedan Chen, Yong Zhang, Jingwen Liu, Jiebai Zhou, Hairong Bao, Donghui Zhang, Yijun Song, Yang Shao, Yuanlin Song   +11 more
wiley   +1 more source

Chemoresistome mapping in individual breast cancer patients unravels diversity in dynamic transcriptional adaptation

Molecular Oncology, EarlyView.
This study used longitudinal transcriptomics and gene‐pattern classification to uncover patient‐specific mechanisms of chemotherapy resistance in breast cancer. Findings reveal preexisting drug‐tolerant states in primary tumors and diverse gene rewiring patterns across patients, converging on a few dysregulated functional modules. Despite receiving the
Maya Dadiani, Gilgi Friedlander, Gili Perry, Nora Balint‐Lahat, Shlomit Gilad, Dana Morzaev‐Sulzbach, Anjana Shenoy, Noa Bossel Ben‐Moshe, Anya Pavlovsky, Rinat Bernstein‐Molho, Eytan Domany, Iris Barshack, Tamar Geiger, Bella Kaufman, Einav Nili Gal‐Yam   +14 more
wiley   +1 more source